ETON NASDAQ
Eton Pharmaceuticals, Inc.
1W: -4.0%
1M: -10.7%
3M: +45.6%
YTD: +240.5%
1Y: +173.2%
3Y: +1082.9%
5Y: +1005.0%
$55.36
+3.38 (+6.50%)
Weekly Expected Move ±9.5%
$45
$50
$55
$61
$66
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
9 relationships8
As Filer
counterparties named
1
As Counterparty
mentioned by others
4
Rel. Types
2021-04-08
Earliest Filing
2026-03-02
Latest Filing
target: 4
partner: 2
licensee: 1
acquirer: 1
Counterparties (Filed by ETON)
8 relationshipsCompanies named in ETON's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Pierre Fabre Medicament Sas | — | licensee | Licensor of HEMANGEOL (propranolol) oral solution rights to Eton Pharmaceuticals, Inc. | 2026-03-02 | View |
| Ipsen S.A. | — | target | Sold Increlex to Eton Pharmaceuticals, Inc. | 2025-11-18 | View |
| Ipsen S.A. | — | acquirer | Seller of the Increlex product in the acquisition completed by Eton Pharmaceuticals, Inc. | 2025-05-02 | View |
| Teva Pharmaceuticals USA, Inc. | — | target | Sold Galzin (zinc acetate) assets and European rights to Eton Pharmaceuticals, Inc. | 2025-01-03 | View |
| Ipsen S.A. | — | target | Sold Increlex (mecasermin injection) to Eton Pharmaceuticals, Inc. | 2024-12-20 | View |
| AMMTeK | — | partner | Licensing agreement for U.S. rights to Amglidia (glyburide oral suspension) | 2024-11-25 | View |
| Ipsen Biopharmaceuticals, Inc. | — | target | Seller of Increlex (mecasermin injection) acquired by Eton Pharmaceuticals | 2024-10-03 | View |
| Ipsen S.A. | — | partner | Parent company of Ipsen Biopharmaceuticals, Inc. | 2024-10-03 | View |
Mentioned As Counterparty
1 mentionsOther companies that named ETON in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-28 | Other Events; Exhibits | View | |
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-08-05 | Material Agreement; Acquisition/Disposition; Exhibits | Agreement Acquisition | View |
| 2026-08-04 | Officer/Director Change | View | |
| 2026-07-29 | Other Events; Exhibits | View | |
| 2026-06-09 | Shareholder Vote | View | |
| 2026-05-19 | Material Agreement; Acquisition/Disposition; Exhibits | Agreement Acquisition | View |
| 2026-05-14 | Earnings Release; Exhibits | View | |
| 2026-05-01 | Other Events; Exhibits | View | |
| 2026-04-27 | Other Events; Exhibits | View | |
| 2026-04-16 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-04-15 | Material Agreement; Financial Obligation; Exhibits | Agreement | View |
| 2026-03-02 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Financ | Agreement Acquisition | View |
| 2026-02-25 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-02 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-04 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-18 | Completion of Acquisition or Disposition of Assets; Financial Statements and Exhibits | Acquisition | View |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-08 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR